Maze Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(116,904) | $(96,552) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,220 | 1,904 |
| Stock-based compensation expense | 24,839 | 10,327 |
| Non-cash lease expense | 2,531 | 2,330 |
| Amortization of premiums (discounts) on marketable securities, net | (141) | (278) |
| Amortization of debt discount and debt issuance costs | 660 | — |
| Other items, net | 18 | 21 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (488) | (2,508) |
| Other assets | (213) | 374 |
| Accounts payable | 2,766 | 1,098 |
| Accrued expenses and other liabilities | 2,581 | 1,519 |
| Operating lease liabilities | (2,784) | (2,445) |
| Long-term liabilities | (1,094) | — |
| Net cash used in operating activities | (87,009) | (84,210) |
| Investing activities | ||
| Purchases of marketable securities | (254,153) | (66,815) |
| Maturities of marketable securities | 101,000 | — |
| Purchases of property and equipment | (488) | (760) |
| Net cash used in investing activities | (153,641) | (67,575) |
| Financing activities | ||
| Proceeds from underwritten registered offering, net | 145,659 | — |
| Payment of underwritten registered offering costs | (1,090) | — |
| Proceeds from debt issuance, net | 39,401 | — |
| Payment of debt issuance costs | (939) | — |
| Proceeds from at-the-market offering, net | 14,597 | — |
| Proceeds from exercise of stock option awards | 6,944 | 2,135 |
| Proceeds from issuance of common stock under the 2025 Employee Stock Purchase Plan | 998 | 612 |
| Proceeds from private placement, net | — | 141,750 |
| Payment of private placement offering costs | (11) | (2) |
| Proceeds from initial public offering, net | — | 130,200 |
| Payment of initial public offering costs | — | (2,448) |
| Payment of success fee derivative | — | (500) |
| Net cash provided by financing activities | 205,559 | 271,747 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (35,091) | 119,962 |
| Cash, cash equivalents and restricted cash at beginning of the period | 190,335 | 197,900 |
| Cash, cash equivalents and restricted cash at end of the period | $155,244 | $317,862 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Purchases of property and equipment recorded in accounts payable and accrued expenses and other current liabilities | $59 | $34 |
| Offering costs recorded in accounts payable and accrued expenses and other current liabilities | $213 | $405 |
| Reconciliation to cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $154,156 | $316,773 |
| Restricted cash | 1,088 | 1,089 |
| Total cash, cash equivalents and restricted cash | $155,244 | $317,862 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.